S
0.074
0.00 (0.00%)
| Previous Close | 0.074 |
| Volume | 28,502,598 |
| 52 Weeks Range |
| Profit Margin | -124.61% |
| Operating Margin (TTM) | -460.26% |
| Diluted EPS (TTM) | -0.360 |
| Quarterly Revenue Growth (YOY) | 1,238.30% |
| Total Debt/Equity (MRQ) | 507.05% |
| Current Ratio (MRQ) | 0.760 |
| Operating Cash Flow (TTM) | -44.62 M |
| Levered Free Cash Flow (TTM) | -20.65 M |
| Return on Assets (TTM) | -46.95% |
| Return on Equity (TTM) | -257.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Sangamo Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Value 35% | -5.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -5.0 |
| Timing 35% | 0.0 |
| AI Technical info | NA |
| Technical Oscillators info | 0.0 |
| Technical Moving Averages info | 0.0 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -17.9% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | NA |
| Final Score | -2.12 |
Select this tab to load the latest available analysis.
|
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington’s Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.75% |
| % Held by Institutions | 22.78% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |